glp 1 effect on liver Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty disease? GLP-1 therapy's potential in treating
Description
The GIP receptor activation is not incidental
We did not obtain informed consent from individual participants involved in our study because we used anonymized data compiled from EMRs
Multiple cardiovascular outcomes trials (CVOTs) have shown significant reductions in major adverse cardiovascular events (MACE), which typically includes cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke
it is a GIP/GLP-1 linear chimeric peptide consisting of 39 amino acids
